Heartport
This article was originally published in The Gray Sheet
Executive Summary
New CEO effective May 7 is Frank Fischer, who served as president and CEO of Ventritex between 1987 and 1997. Fischer replaces company co-founder Wesley Sterman, MD, who remains chairman of the board. In announcing Fischer's appointment, the company reports that it is streamlining operations by reducing its U.S. work force by about one-third, scaling back manufacturing capacity and cutting general and administrative expenses "in several areas." The company, which manufactures the Port-Access minimally invasive system for stopped-heart coronary artery bypass grafting procedures, will book a charge related to the restructuring. Heartport says it is expanding its sales force "by moving more clinical training specialists into the field to work directly with surgical teams at their hospitals"
You may also be interested in...
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.
Generic Or Innovator? Sandoz Sues CMS Over Potential Change In Rebate Classification
Sandoz argued against paying higher rebates for two of its drugs via the Centers for Medicare and Medicaid Services’ Medicaid drug rebate program in a US court six years after the suggestion was first made.